| Identification | Back Directory | [Name]
2-Methyl-2-[4-[3-methyl-2-oxo-8-[(pyridin-3-yl)ethynyl]-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile | [CAS]
853910-61-9 | [Synonyms]
NVP-BBD130
NVP-BBD130 - BBD 130
2-Methyl-2-[4-[3-methyl-2-oxo-8-[(pyridin-3-yl)ethynyl]-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile | [Molecular Formula]
C28H21N5O | [MDL Number]
MFCD17215199 | [MOL File]
853910-61-9.mol | [Molecular Weight]
443.499 |
| Hazard Information | Back Directory | [Uses]
NVP-BBD130 is a potent, stable, ATP-competitive and orally active dual PI3K and mTOR inhibitor[1]. NVP-BBD130 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
NVP-BBD130 (40 mg/kg; p.o.; daily for 2 weeks) efficiently attenuates tumor growth at primary and lymph node metastatic sites with no obvious toxicity, and is well tolerant in B16BL6 mouse melanoma model[1]. | Animal Model: | C57BL6 mice, syngeneic B16BL6 mouse melanoma model[1] | | Dosage: | 40 mg/kg | | Administration: | Oral administration, daily for 2 weeks | | Result: | Reduced primary tumor size, showed a significant reduction in the size of the cervical lymph node metastasis. |
| [References]
[1] Marone R, et al. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res. 2009 Apr;7(4):601-13. DOI:10.1158/1541-7786.MCR-08-0366 |
|
|